Your participation will allow you to have firsthand experience with developing new medical treatments that may be beneficial to others. Current treatment methods for neurologic disorders are only available because of volunteer participants in clinical trials. Clinical trial information is excerpted from www.clinicaltrials.gov.
A Clinical Study of NLY01 in Patients with Early Parkinson's Disease (NCT04154072)
Objective: Phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease Eligibility: Individuals 30 to 80 years old, with early-stage Parkinson’s Disease, not on any current treatments
P.I.: Emile Moukheiber, M.D.
Contact: Kori Ribb; 410-614-2216
Longitudinal Biomarkers of Individuals with Atypical Parkinsonism (IRB00062534)
Eligibility: Individuals w/ dx of MSA, PSP, CBS or DLB; able to complete annual follow-up visits for 5+ years
P.I.: Alex Pantelyat, M.D.
Contact: Vanessa Johnson; 410-616-2815
Udall Center Brain Donation Program (NA_00032761)
Objective: Examine the pathological changes in the brain tissue of individuals diagnosed with PD or related disorders as compared to controls
Eligibility: Individuals diagnosed with PD or atypical PD and those without a neurological diagnosis
P.I.: Liana Rosenthal, M.D.
Contact: Catherine Bakker; 410-616-2814
4RTNI-2 (NA_00130505)
Objective and Eligibility: The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. Select individuals with CBD, PSP or variant PSP; healthy controls, caregiver component
P.I.: Alex Pantelyat, M.D.
Contact: Diane Lanham; 443-287-4156
Biomarker Discovery and Validation in Progressive Supranuclear Palsy (DIVAPSP) (IRB00173663)
Eligibility: Individuals with a diagnosis of PD or PSP, healthy controls; (caregiver/study partner also required for participation)
P.I.: Alex Pantelyat, M.D.
Contact: AJ Hall; 410-616-2813
Multimodal MRI in PSP (IRB00062534)
Eligibility: Individuals diagnosed w/ PSP (PSP-RS, PSP-SL, PSPCBS) or PPA; willingness/ability to complete MRI and lumbar puncture
P.I.: Alex Pantelyat, M.D.
Contact: Diane Lanham; 443-287-4156
Dystonia Coalition (NA_00074297)
Objective: Create an international repository to learn more about dystonia, treatment methods and patient response
Eligibility: Individuals over the age of 18 who have primary dystonia
P.I.: Alex Pantelyat, M.D.
Contact: Sydney Baybayan; 410-955-6692
PET Study for individuals with REM Sleep Behavioral Disorder, PD and Healthy Controls (IRB00237032 )
Objective: A PET scan study to determine if there is inflammation in the brain of people with early Parkinson's.
Eligibility: Age 50-80 and healthy controls.
P.I.: Kelly Mills, M.D.
Contact: Emily Carman; 410-955-8909
The Parkinson’s Progression Markers Initiative (PPMI) 2.0 (NCT04477785)
Objective: The overall goal of PPMI 2.0 is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability. Including healthy controls
P.I.: Emile Moukheiber, M.D.
Contact: Sydney Babayan; 410-955-6692
Feasibility and Preliminary Effects of Using a Music-based, Rhythmmodulating Wearable Sensor System in the Community in Persons with Parkinson’s Disease (MedRhythms Study)
Objective: The purpose of this clinical study is to evaluate the effects of music, tailored to the participant's cadence, on adherence, quality of life, gait speed, functional mobility, and walking activity in individuals with Parkinson disease when used in the home and community environment.
P.I.: Alex Pantelyat, M.D.
Contact: Colin McGregor; 410-616-2816
Molecular Imaging of Depression in Aging and Parkinson’s Disease (Controls and Patients with Parkinson’s Disease and Depression) (IRB00068329)
Overview: Are you over 60 and feeling depressed? Symptoms of depression in older adults are common yet often go undetected. Symptoms could include feelings of sadness or hopelessness, loss of energy, inability to enjoy pleasurable activities, changes in appetite or sleeping patterns, or poor concentration/memory. If you are feeling depressed, not taking antidepressant medication and in good physical health you may be eligible to participate in a research study involving treatment. Qualified people will participate at no cost to them and will be compensated for their time and transportation
P.I.: Gwenn Smith, Ph.D.
Contact: 410-550-4192
A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)(NCT04006210)
Overview: A double-blind study of subcutaneous levodopa infusion to evaluate efficacy as compared to oral levodopa management in moderate to advanced PD.
P.I.: Ankur Butala, M.D.
Contact: Emily Carman; 410-955-8909
Biomarkers for Ataxia and Multiple System Atrophy (IRB00205116 )
Objective: A major impediment to developing new treatments for neurological diseases is the absence of biological markers for early diagnosis and treatment response. Currently the diagnosis of ataxia and MSA is based on the presence of clinical signs and, in some cases, genetic testing. The research seeks to identify biomarkers for ataxia and MSA in an effort to improve diagnosis and therapeutics for these diseases.
P.I.: Liana Rosenthal, M.D.
Contact: Michelle Joyce; mjoyce14@jhmi.edu
Visual Hallucinations and Memory Impairment in Parkinson’s Disease: the Role of Hippocampal Networks (IRB00242772)
Objective: The goal of this project is to assess the role of hippocampal networks in memory impairment and hallucinations in PD and determine whether hippocampal network dysfunction predicts greater cognitive and functional decline longitudinally.
P.I.: Arnold Bakker, Ph.D., MA and Gregory Pontone, M.D.
Contact: 410-502-4797 or memory@jhmi.edu